Our study results demonstrate that in patients with increasing PSA-values at least two years after primary radiotherapy for prostate cancer, combined imaging with mp-MRI and PSMA PET/CT has a positive predictive value of 97.6% to find recurrent prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.